| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
43,990,000 |
| Market
Cap: |
599.14(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.31 - $15.24 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile REGENXBIO is a clinical-stage biotechnology company. Co.'s product candidates include: RGX-314, which is being developed as a gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other additional chronic retinal conditions which cause total or partial vision loss for patients in the U.S., Europe and Japan; RGX-121, which is for the treatment of Mucopolysaccharidosis Type II; RGX-111, which is for the treatment of Mucopolysaccharidosis Type I; RGX-181, which is for the treatment of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease; and RGX-381, which is for the treatment of ocular manifestations of CLN2 disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
36,169 |
56,771 |
220,497 |
| Total Sell Value |
$0 |
$416,599 |
$579,645 |
$3,228,261 |
| Total People Sold |
0 |
1 |
2 |
4 |
| Total Sell Transactions |
0 |
3 |
4 |
20 |
| End Date |
2025-10-19 |
2025-07-18 |
2025-01-17 |
2024-01-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pakola Steve |
Chief Medical Officer |
• – – |
2026-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
65,847 |
258,317 |
|
- |
|
| Chan Mitchell |
Chief Financial Officer |
• – – |
2026-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
73,749 |
127,717 |
|
- |
|
| Christmas Patrick J. |
Chief Strategy & Legal Officer |
• – – |
2026-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
73,749 |
215,367 |
|
- |
|
| Malzahn Craig |
Chief Technology Officer |
• – – |
2026-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
65,847 |
82,194 |
|
- |
|
| Simpson Curran |
Chief Executive Officer |
• • – |
2026-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
144,864 |
342,467 |
|
- |
|
| Christmas Patrick J. |
Chief Strategy & Legal Officer |
• – – |
2026-01-02 |
4 |
D |
$14.40 |
$141,019 |
D/D |
(9,793) |
141,618 |
|
- |
|
| Pakola Steve |
Chief Medical Officer |
• – – |
2026-01-02 |
4 |
D |
$14.40 |
$262,757 |
D/D |
(18,247) |
192,470 |
|
- |
|
| Malzahn Craig |
Chief Technology Officer |
• – – |
2026-01-02 |
4 |
D |
$14.40 |
$17,827 |
D/D |
(1,238) |
16,347 |
|
- |
|
| Simpson Curran |
Chief Executive Officer |
• • – |
2026-01-02 |
4 |
D |
$14.40 |
$267,250 |
D/D |
(18,559) |
197,603 |
|
- |
|
| Simpson Curran |
Chief Executive Officer |
• • – |
2025-10-09 |
4 |
AS |
$12.62 |
$262,635 |
D/D |
(20,811) |
216,162 |
|
12% |
|
| Simpson Curran |
Chief Executive Officer |
• • – |
2025-09-29 |
4 |
AS |
$10.03 |
$76,469 |
D/D |
(7,624) |
236,973 |
|
38% |
|
| Simpson Curran |
Chief Executive Officer |
• • – |
2025-09-10 |
4 |
AS |
$10.02 |
$77,495 |
D/D |
(7,734) |
244,597 |
|
42% |
|
| Chan Mitchell |
Chief Financial Officer |
• – – |
2025-09-01 |
4 |
D |
$8.93 |
$43,766 |
D/D |
(4,901) |
53,968 |
|
- |
|
| Malzahn Craig |
Chief Technology Officer |
• – – |
2025-09-01 |
4 |
D |
$8.93 |
$2,090 |
D/D |
(234) |
17,585 |
|
- |
|
| Christmas Patrick J. |
Chief Strategy & Legal Officer |
• – – |
2025-08-01 |
4 |
D |
$8.19 |
$38,485 |
D/D |
(4,699) |
151,411 |
|
- |
|
| Simpson Curran |
Chief Executive Officer |
• • – |
2025-07-01 |
4 |
D |
$8.23 |
$38,689 |
D/D |
(4,701) |
252,331 |
|
- |
|
| Tasse Daniel |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
19,054 |
|
- |
|
| Stump David C |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
19,054 |
|
- |
|
| Migausky George V |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
19,054 |
|
- |
|
| Zachary Jennifer |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
22,064 |
|
- |
|
| Bennett Jean |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
19,054 |
|
- |
|
| Karabelas Argeris N |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
19,054 |
|
- |
|
| Glucksmann Alexandra |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
19,054 |
|
- |
|
| Mills Kenneth T. |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
482,871 |
|
- |
|
| Fox Allan M. |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
19,054 |
|
- |
|
470 Records found
|
|
Page 1 of 19 |
|
|
0.14 (1.02%) 
